HighTide Therapeutics, Inc. (HKG:2511)

HighTide Therapeutics Ratios and Metrics

Market cap in millions HKD. Fiscal year is January - December.

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jul 9, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Market Capitalization	1,468	1,685	654	6,671	-	-
Market Cap Growth	-8.87%	157.80%	-90.20%	-	-	-
Enterprise Value	1,114	1,363	73	8,025	-	-
Last Close Price	2.57	2.95	1.27	12.96	-	-
PB Ratio	3.62	4.15	1.45	8.62	-	-
P/TBV Ratio	4.30	4.93	1.45	8.62	-	-
Debt / Equity Ratio	0.35	0.35	0.18	0.02	-2.70	-3.72
Net Debt / Equity Ratio	-1.03	-1.03	-0.97	-1.02	-0.91	-0.91
Net Debt / EBITDA Ratio	1.69	1.69	0.93	1.61	-1.91	-1.88
Net Debt / FCF Ratio	2.25	2.25	1.36	2.01	-2.49	-2.69
Quick Ratio	5.27	5.27	4.47	9.32	0.64	26.85
Current Ratio	5.42	5.42	4.67	9.76	0.65	27.17
Return on Equity (ROE)	-58.85%	-58.85%	-67.76%	-808.89%	-	-
Return on Assets (ROA)	-25.15%	-25.15%	-41.03%	-33.94%	-17.29%	-
Return on Capital Employed (ROCE)	-49.30%	-49.30%	-98.80%	-62.70%	48.70%	-17.60%
Earnings Yield	-18.57%	-16.17%	-62.15%	-15.51%	-	-
FCF Yield	-12.66%	-11.03%	-49.28%	-5.90%	-	-
Buyback Yield / Dilution	-6.12%	-6.12%	-74.08%	-1.91%	-506.17%	-

Data Source: S&P Global Market Intelligence Last updated: Dec 31, 2025

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Jul 9, 2026

Data Sources Report a data error